LETTER TO THE EDITOR
Measurement of antifactor VIII antibody titre in the presence of emicizumab; Use of chromogenic Bethesda assays
Annette Bowyer,
Annette Bowyer
Department of Coagulation, Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK
Search for more papers by this author Steve Kitchen,
Steve Kitchen
Department of Coagulation, Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK
Search for more papers by this author Rhona Maclean,
Rhona Maclean
Department of Coagulation, Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK
Search for more papers by this author
Annette Bowyer,
Annette Bowyer
Department of Coagulation, Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK
Search for more papers by this author Steve Kitchen,
Steve Kitchen
Department of Coagulation, Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK
Search for more papers by this author Rhona Maclean,
Rhona Maclean
Department of Coagulation, Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK
Search for more papers by this author
First published: 25 March 2021
Correspondence
Annette Bowyer, Department of Coagulation, Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK.
Email: [email protected]
No abstract is available for this article.
REFERENCES
- 1Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia. Haemophilia. 2020; 26(S6): 1-158.
- 2Hay CRM, Ludlam CA, Colvin BT, et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Throm Haemost. 1998; 79: 762-766.
- 3Eckhardt CL, van Velzen AS, Peters M, et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood. 2013; 122: 1954-1962.
- 4Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K. Factor VIII–mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016; 374: 2044-2053.
- 5Adamkewicz J, Soeda T, Kotani N, Calatzis A, Levy G. Effect of Emicizumab (ACE910) – A Humanized Bispecific Antibody Mimicking FVIII Cofactor Function – on coagulation assays commonly in use for monitoring of Hemophilia A patients. Haemophilia. 2017; 23(S3): 4.
- 6Adamkewicz J, Kim B, Steinbusch D, Calatzis A. Measurement of FVIII inhibitor titer using a chromogenic Bethesda assay (CBA) in the presence of emicizumab (ACE910), a humanized bispecific antibody mimicking FVIIIa cofactor function. Haemophilia. 2017; 23(S3): 3 (Abstract).
- 7Bowyer AE, Kitchen S, Maclean RM. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors. Haemophilia. 2020; 26(3): 536-542.
- 8Unterberger M, Wagner L, Binder NB. Use of a chromogenic factor VIII activity determination in haemophilia A plasma of patients under emicizumab treatment. Res Pract Thromb Haemost. 2019; 3(S1): 1-891.
- 9Adamkewicz J, Chen D, Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost. 2019; 119(7): 1084-1093.
- 10Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost. 1995; 72(2): 247-251.
